Guardant Health

We have launched our upgraded Guardant360 TissueNext test featuring an expanded gene panel of 498 biomarkers and a faster turnaround time for results. “In addition to identifying guideline-recommended biomarkers, the upgraded test now provides more comprehensive gene coverage, so oncologists can make better informed decisions about the optimal treatment strategy for their patients with advanced cancer…” said co-CEO Helmy Eltoukhy.

Today at #ASCO24, research partner Washington University School of Medicine in St. Louis will lead an oral presentation highlighting a study demonstrating the use of liquid biopsy in addressing racial inequities in the use of targeted therapies and enrollment in clinical trials for advanced breast cancer. The study, part of an ongoing collaboration with Precision Medicine Academic Consortium, is aimed at advancing the use of liquid biopsy in patients with metastatic breast cancer.

#ASCO24 is underway and we're excited to connect with the oncology community! Stop by booth #28115 to learn more about our end-to-end precision oncology solutions and our work to disrupt the paradigm of cancer monitoring.

We're honored to be recognized on TIME's list of the 100 Most Influential Companies of 2024. As our Co-CEO Helmy Eltoukhy noted, “We tirelessly pursue our mission to conquer cancer with data because our progress means giving more people more time free from cancer. We are grateful for this recognition… as it is a strong reflection of our entire team’s commitment to transforming patient care through critical insights into disease drivers, advanced blood and tissue tests, real-world data, and AI analytics.” #TIME100Companies

Join us at #ASCO24 as we present data highlighting important developments in cancer care using liquid biopsy to identify epigenomic biomarkers. Visit booth 28115 to learn more.

Today, we pause to pay tribute and honor the brave heroes who have made the ultimate sacrifice while serving in the armed forces.

Today the FDA’s Medical Devices Advisory Committee panel strongly recommended FDA approval of our Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease. The committee’s support for the approval of Shield reinforces the crucial role that a blood test option can have in improving screening rates and potentially reducing preventable CRC-related deaths.

ICYMI: UC San Diego Professor of Medicine Samir Gupta, MD discusses how new screening options, such as our Shield blood test, could help elevate colorectal cancer screening rates, identify treatable cancers, and reduce the number of deaths from the disease.

Today we announced an important achievement: EU IVDR certification for our Guardant360 CDx blood test. As co-CEO Helmy Eltoukhy noted, “The IVDR certification for the Guardant360 CDx liquid biopsy is a significant milestone for cancer care in the EU, as the test provides faster access to comprehensive genomic profiling for oncologists and, more importantly, for the patients they treat.”

Following our milestone announcement of 500 peer-reviewed publications, we sat down with our Chief Medical Officer Dr. Craig Eagle to discuss the significance of the achievement along with the impact on patient care. Watch the full interview: https://lnkd.in/eH2k9HJp